1
|
Soltan MA, Eldeen MA, Eid RA, Alyamani NM, Alqahtani LS, Albogami S, Jafri I, Park MN, Alsharif G, Fayad E, Mohamed G, Osman R, Kim B, Zaki MSA. A pan-cancer analysis reveals CHD1L as a prognostic and immunological biomarker in several human cancers. Front Mol Biosci 2023; 10:1017148. [PMID: 37033447 PMCID: PMC10076660 DOI: 10.3389/fmolb.2023.1017148] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 02/27/2023] [Indexed: 04/11/2023] Open
Abstract
Introduction: Several recent studies pointed out that chromodomain-helicase-DNA-binding protein 1-like (CHD1L) is a putative oncogene in many human tumors. However, up to date, there is no pan-cancer analysis performed to study the different aspects of this gene expression and behavior in tumor tissues. Methods: Here, we applied several bioinformatics tools to make a comprehensive analysis for CHD1L. Firstly we assessed the expression of CHD1L in several types of human tumors and tried to correlate that with the stage and grade of the analyzed tumors. Following that, we performed a survival analysis to study the correlation between CHD1L upregulation in tumors and the clinical outcome. Additionally, we investigated the mutation forms, the correlation with several immune cell infiltration, and the potential molecular mechanisms of CHD1L in the tumor tissue. Result and discussion: The results demonstrated that CHD1L is a highly expressed gene across several types of tumors and that was correlated with a poor prognosis for most cancer patients. Moreover, it was found that CHD1L affects the tumor immune microenvironment by influencing the infiltration level of several immune cells. Collectively, the current study provides a comprehensive overview of the oncogenic roles of CHD1L where our results nominate CHD1L as a potential prognostic biomarker and target for antitumor therapy development.
Collapse
Affiliation(s)
- Mohamed A. Soltan
- Department of Microbiology and Immunology, Faculty of Pharmacy, Sinai University, Ismailia, Egypt
- *Correspondence: Mohamed A. Soltan, ; Bonglee Kim,
| | - Muhammad Alaa Eldeen
- Cell Biology, Histology and Genetics Division, Zoology Department, Faculty of Science, Zagazig University, Zagazig, Egypt
| | - Refaat A. Eid
- Pathology Department, College of Medicine, King Khalid University, Abha, Saudi Arabia
| | - Najiah M. Alyamani
- Department of Biology, College of Science, University of Jeddah, Jeddah, Saudi Arabia
| | - Leena S. Alqahtani
- Department of Biochemistry, College of Science, University of Jeddah, Jeddah, Saudi Arabia
| | - Sarah Albogami
- Department of Biotechnology, College of Sciences, Taif University, Taif, Saudi Arabia
| | - Ibrahim Jafri
- Department of Biotechnology, College of Sciences, Taif University, Taif, Saudi Arabia
| | - Moon Nyeo Park
- Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, South Korea
| | - Ghadi Alsharif
- College of Clinical Laboratory Sciences, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
| | - Eman Fayad
- Department of Biotechnology, College of Sciences, Taif University, Taif, Saudi Arabia
| | - Gamal Mohamed
- Department of Human Anatomy, Jazan University, Jazan, Kingdom of Saydi Arabia
| | - Rihab Osman
- Department of Anatomy, College of Medicine, King Khalid University, Abha, Saudi Arabia
| | - Bonglee Kim
- Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, South Korea
- *Correspondence: Mohamed A. Soltan, ; Bonglee Kim,
| | - Mohamed Samir A. Zaki
- Anatomy Department, College of Medicine, King Khalid University, Abha, Saudi Arabia
- Department of Histology and Cell Biology, College of Medicine, Zagazig University, Zagazig, Egypt
| |
Collapse
|
2
|
Osio A, Vignon-Pennamen MD, Pedeutour F, Le Maignan C, Koskas F, Lebbé C, Janin A, Battistella M. PDGFRa amplification in multiple skin lesions of undifferentiated pleomorphic sarcoma: A clue for intimal sarcoma metastases. J Cutan Pathol 2017; 44:477-479. [PMID: 28105789 DOI: 10.1111/cup.12907] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Revised: 01/12/2017] [Accepted: 01/16/2017] [Indexed: 12/01/2022]
Abstract
A 62-year-old human immunodeficiency virus-positive man was admitted for multiple cutaneous and subcutaneous nodules on his lower limbs, corresponding to an undifferentiated proliferation of spindle and pleomorphic cells, with irregular nuclei and numerous mitoses. The tumor cells were negative for a large panel of immunohistochemical markers, except CD10. MDM2 immunohistochemical staining was also negative, leading to the diagnosis of Fédération Nationale des Centres de Lutte contre le Cancer grade III undifferentiated pleomorphic sarcoma (UPS). Array-comparative genomic hybridization showed a highly complex karyotype, with amplification of the 4q12 region, an area that contains only the platelet-derived growth factor receptor α (PDGFRa) gene. This amplification of PDFGRa, molecular hallmark of intimal sarcoma (IS), led to the diagnosis of skin IS metastasis. A positron emission tomography showed a hypermetabolic mass protruding in the preaortic area, consistent with the diagnosis of aortic IS. Our study shows that a rare differential diagnosis in peripheral UPS can be IS skin metastasis, and underlines the importance of molecular analyses in UPS.
Collapse
Affiliation(s)
- Amélie Osio
- Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1165, Paris, France.,INSERM, U1165-Paris, Paris, France.,Laboratoire de Pathologie, Hôpital Saint-Louis AP-HP, Paris, France
| | - Marie-Dominique Vignon-Pennamen
- Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1165, Paris, France.,INSERM, U1165-Paris, Paris, France.,Laboratoire de Pathologie, Hôpital Saint-Louis AP-HP, Paris, France
| | - Florence Pedeutour
- Laboratoire de Biologie, Centre Hospitalier Universitaire de Nice, Nice, France
| | | | - Fabien Koskas
- Service de Chirurgie Vasculaire, Hôpital la Pitié Salpétrière AP-HP, Paris, France
| | - Célèste Lebbé
- Service de Dermatologie, Hôpital Saint-Louis AP-HP, Paris, France
| | - Anne Janin
- Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1165, Paris, France.,INSERM, U1165-Paris, Paris, France.,Laboratoire de Pathologie, Hôpital Saint-Louis AP-HP, Paris, France
| | - Maxime Battistella
- Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1165, Paris, France.,INSERM, U1165-Paris, Paris, France.,Laboratoire de Pathologie, Hôpital Saint-Louis AP-HP, Paris, France
| |
Collapse
|
3
|
Sarhadi VK, Lahti L, Scheinin I, Ellonen P, Kettunen E, Serra M, Scotlandi K, Picci P, Knuutila S. Copy number alterations and neoplasia-specific mutations inMELK,PDCD1LG2, TLN1, andPAX5at 9p in different neoplasias. Genes Chromosomes Cancer 2014; 53:579-88. [DOI: 10.1002/gcc.22168] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2013] [Accepted: 03/09/2014] [Indexed: 12/16/2022] Open
Affiliation(s)
- Virinder Kaur Sarhadi
- Department of Pathology; Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital; Helsinki Finland
| | - Leo Lahti
- Department of Veterinary Bioscience; University of Helsinki, Finland and Laboratory of Microbiology, Wageningen University; The Netherlands
| | - Ilari Scheinin
- Department of Pathology; Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital; Helsinki Finland
- Department of Pathology; VU University Medical Center; Amsterdam The Netherlands
| | - Pekka Ellonen
- Institute for Molecular Medicine Finland, University of Helsinki; Biomedicum Helsinki 2U Helsinki Finland
| | - Eeva Kettunen
- Health and Work Ability; Finnish Institute of Occupational Health; Helsinki Finland
| | - Massimo Serra
- Laboratory of Experimental Oncology; Orthopaedic Rizzoli Institute; Bologna Italy
| | - Katia Scotlandi
- Laboratory of Experimental Oncology; Orthopaedic Rizzoli Institute; Bologna Italy
| | - Piero Picci
- Laboratory of Experimental Oncology; Orthopaedic Rizzoli Institute; Bologna Italy
| | - Sakari Knuutila
- Department of Pathology; Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital; Helsinki Finland
| |
Collapse
|
4
|
Abstract
Comprehensive sequencing efforts have revealed the genomic landscapes of common forms of human cancer and ~ 140 driver genes have been identified, but not all of them have been extensively investigated. CHD1L (chromodomain helicase/ATPase DNA binding protein 1-like gene) or ALC1 (amplified in liver cancer 1) is a newly identified oncogene located at Chr1q21 and it is amplified in many solid tumors. Functional studies of CHD1L in hepatocellular carcinoma and other tumors strongly suggested that its oncogenic role in tumorigenesis is through unleashed cell proliferation, G1/S transition and inhibition of apoptosis. The underlying mechanisms of CHD1L activation may disrupt the cell death program via binding the apoptotic protein Nur77 or through activation of the AKT pathway by up-regulation of CHD1L-mediated target genes (e.g., ARHGEF9, SPOCK1 or TCTP). CHD1L is now considered to be a novel independent biomarker for progression, prognosis and survival in several solid tumors. The accumulated knowledge about its functions will provide a focus to search for targeted treatment in specific subtypes of tumors.
Collapse
Affiliation(s)
- Wen Cheng
- Department of Urology, Nanjing Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, Jiangsu, P,R, of China.
| | | | | |
Collapse
|
5
|
Iacobucci I, Ferrari A, Lonetti A, Papayannidis C, Paoloni F, Trino S, Storlazzi CT, Ottaviani E, Cattina F, Impera L, Abbenante MC, Vignetti M, Vitale A, Potenza L, Paolini S, Soverini S, Pane F, Luppi M, Foà R, Baccarani M, Martinelli G. CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1–Positive Acute Lymphoblastic Leukemia Patients. Clin Cancer Res 2011; 17:7413-23. [DOI: 10.1158/1078-0432.ccr-11-1227] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Niini T, Lahti L, Michelacci F, Ninomiya S, Hattinger CM, Guled M, Böhling T, Picci P, Serra M, Knuutila S. Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone. Genes Chromosomes Cancer 2011; 50:291-306. [DOI: 10.1002/gcc.20851] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2010] [Accepted: 12/02/2010] [Indexed: 12/13/2022] Open
|
7
|
Mohseny AB, Tieken C, van der Velden PA, Szuhai K, de Andrea C, Hogendoorn PCW, Cleton-Jansen AM. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma. Genes Chromosomes Cancer 2010; 49:1095-103. [DOI: 10.1002/gcc.20817] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
8
|
Chari R, Thu KL, Wilson IM, Lockwood WW, Lonergan KM, Coe BP, Malloff CA, Gazdar AF, Lam S, Garnis C, MacAulay CE, Alvarez CE, Lam WL. Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev 2010; 29:73-93. [PMID: 20108112 DOI: 10.1007/s10555-010-9199-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Advances in high-throughput, genome-wide profiling technologies have allowed for an unprecedented view of the cancer genome landscape. Specifically, high-density microarrays and sequencing-based strategies have been widely utilized to identify genetic (such as gene dosage, allelic status, and mutations in gene sequence) and epigenetic (such as DNA methylation, histone modification, and microRNA) aberrations in cancer. Although the application of these profiling technologies in unidimensional analyses has been instrumental in cancer gene discovery, genes affected by low-frequency events are often overlooked. The integrative approach of analyzing parallel dimensions has enabled the identification of (a) genes that are often disrupted by multiple mechanisms but at low frequencies by any one mechanism and (b) pathways that are often disrupted at multiple components but at low frequencies at individual components. These benefits of using an integrative approach illustrate the concept that the whole is greater than the sum of its parts. As efforts have now turned toward parallel and integrative multidimensional approaches for studying the cancer genome landscape in hopes of obtaining a more insightful understanding of the key genes and pathways driving cancer cells, this review describes key findings disseminating from such high-throughput, integrative analyses, including contributions to our understanding of causative genetic events in cancer cell biology.
Collapse
Affiliation(s)
- Raj Chari
- Genetics Unit - Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|